AltaML has formed a strategic alliance with Amplitude Venture Capital, a top Canadian firm focused on life sciences and building precision medicine companies. The partnership will look to leverage the possibility of artificial intelligence and machine learning in the biotechnology sector.
"AI is a horizontal enabler — there's no AI industry per se. You've got to actually do something," AltaML co-founder Cory Janssen told Taproot. "So this example of actually teaming up within life sciences is really taking advantage of the talent that is here."
The Edmonton-grown AI studio will share a team member with Amplitude as part of the alliance: AltaML's data science health lead, Alex Hope. He will help to identify investment opportunities, with a focus on Alberta in particular, as well as "projects where the two companies can work together to create, build, and grow a talent base by combining AI acumen with life science expertise."
AltaML, which started developing AI software in Edmonton in 2017, will access Amplitude's expertise to deepen the company's health focus, especially in commercialization.
"By having access to that network and connections, it opens up the door for possibilities for us right here in Edmonton," Janssen said.
"I would argue that there's benefits to this for any startup or researcher that's looking to commercialize innovations at the intersection of health and data."
In turn, AltaML will provide AI expertise for Amplitude's portfolio.